Fibrin Polymerization and its Role in Regulating Hemostasis

  • Michael W. Mosesson
Part of the Veröffentlichungen aus der Geomedizinischen Forschungsstelle der Heidelberger Akademie der Wissenschaften book series (HD AKAD, volume 1990 / 1990/3)


The final phase of in vivo thrombus formation involves generation of a fibrin clot which provides the major structural support and scaffolding for the cellular and other blood elements that comprise the thrombus. Fibrin polymerization begins with the generation of fibrin monomer units by thrombin cleavage of soluble circulating precursor fibrinogen molecules. This is followed by an orderly process of fibril assembly, branching, lateral association, and covalent crosslinking, to form the mature fibrin clot. In addition to the structural function served by fibrin polymer formation, other biological properties develop as a result of the conversion from fibrinogen to fibrin that play a significant physiological role in regulating the rate and extent of clot formation, and clot lysis. In this article, I will summarize the nature of the essential elements and mechanisms that contribute to fibrin gelation, and review some of the special properties of fibrin that provide it with additional roles in hemostatic function and fibrinolysis.


Tissue Plasminogen Activator Factor Xiii Fibrin Clot Thrombin Cleavage Fibrin Polymerization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Al-Mondhiry HAB, Bilezikian SB, Nossel HL (1975) Fibrinogen New York’–an abnormal fibrinogen associated with thromboembolism: functional evaluation. Blood 45: 607–619PubMedGoogle Scholar
  2. Amrani DL, Mosesson MW (1989) Evidence that fibrin crosslinked by factor XIIIa forms alpha-gamma chain crosslinks. Blood 74 (Suppl 1): 212aGoogle Scholar
  3. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobokura M (1979) Congenital deficiency of a2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 63: 877–884PubMedGoogle Scholar
  4. Aoki N, Harpel PC (1984) Inhibitors of the fibrinolytic enzyme system. Sem Thromb Haemostas 10: 24–41Google Scholar
  5. Bailey K, Bettelheim FR, Lorand L, Middlebrook WR (1951) Action of thrombin in the clotting of fibrinogen. Nature 167: 233–234PubMedGoogle Scholar
  6. Berliner LJ, Sugawara Y, Fenton JW, II (1985) Human a-thrombin binding to non-polymerized fibrin-sepharose: evidence for an anionic binding region. Biochemistry 24: 7005–7009PubMedGoogle Scholar
  7. Blombäck B (1958) Studies on the action of thrombic enzymes on bovine fibrinogen as measured by N-terminal analysis. Arkiv Kemi 12: 321–335Google Scholar
  8. Blombäck B, Vestermark A (1958) Isolation of fibrinopeptides by chromatography. Ark Kemi 12: 173–182Google Scholar
  9. Blombäck B, Hessel B, Hogg D (1976) Disulfide bridges in NH2-terminal part of human fibrinogen. Thromb Res 8: 639–658PubMedGoogle Scholar
  10. Bok RA, Mangel WF (1985) Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin. Biochemistry 24: 3279–3286PubMedGoogle Scholar
  11. Budzynski AZ, Olexa SA, Pandya BV (1983) Fibrin polymerization sites in fibrinogen and fibrin fragments. Ann NY Acad Sci 408: 301–314PubMedGoogle Scholar
  12. Buluk K, Januczko T, Olbromski J (1961) Conversion of fibrin to desmofibrin. Nature 191: 1093–1094Google Scholar
  13. Carr ME, Jr., Hermans J (1978) Size and density of fibrin fibers from turbidity. Macromolecules 11: 46–50PubMedGoogle Scholar
  14. Chen R, Doolittle RF (1969) Identification of the polypeptide chains involved in the cross-linking of fibrin. Proc Natl Acad Sci USA 63: 420–427PubMedGoogle Scholar
  15. Chen R, Doolittle RF (1971) ‘y-ycross-linking sites in human and bovine fibrin. Biochemistry 10: 4486–4491Google Scholar
  16. Cheseboro JH, Knatterud G, Roberts R, et al. (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76: 142–154Google Scholar
  17. Chung SI, Lewis MS, Folk JE (1974) Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures. J Biol Chem 249: 940–950PubMedGoogle Scholar
  18. Collen D (1976) Identification and some properties of a new fast reacting plasmin inhibitor in human plasma. Eur. J Biochem 69: 209–216PubMedGoogle Scholar
  19. Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemostas 43: 77–89Google Scholar
  20. Cooke RD, Holbrook JJ (1974) The calcium-induced dissociation of human plasma clotting factor XIII. Biochem J 141: 71–78PubMedGoogle Scholar
  21. Credo RB, Curtis CG, Lorand L (1978) Ca2+-related regulatory function of fibrinogen. Proc Natl Acad Sci USA 75: 4234–4237PubMedGoogle Scholar
  22. Curtis CG, Brown K, Credo RB, et al. (1974) Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry 13: 3774–3780PubMedGoogle Scholar
  23. Doolittle RF, Chen R, Lau F (1971) Hybrid fibrin: Proof of the intermolecular nature of y-ycrosslinking units. Biochem Biophys Res Comm 44: 94–100Google Scholar
  24. Doolittle, RF (1973) Structural details of fibrin stabilization: implications for fibrinogen structure and initial fibrin formation. Thromb Diath Haemorrh 54 (Suppl): 155–165Google Scholar
  25. Doolittle RF (1983) The structure and evolution of vertebrate fibrinogen. Ann NY Acad Sci 408: 13–26PubMedGoogle Scholar
  26. Erickson HP, Fowler WE (1983) Electron microscopy of fibrinogen, its plasmic fragments and small polymers. Ann NY Acad Sci 408: 146–163PubMedGoogle Scholar
  27. Fenton JW, II, Olson TA, Zabinski MP, Wilner GD (1988) Anion-binding exosite of human a-thrombin and fibrin(ogen) recognition. Biochemistry 27: 7106–7112PubMedGoogle Scholar
  28. Ferry JD (1952) The mechanism of polymerization of fibrinogen. Proc Natl Acad Sci USA 38: 566–569PubMedGoogle Scholar
  29. Ferry JD (1988) Structure and rheology of fibrin networks. In: Kramer 0, ed. Biological and synthetic polymer networks. Amsterdam: Elsevier Appl Sci 41–55Google Scholar
  30. Fowler WE, Hantgan RR, Hermans J, Erickson HP (198la) Structure of the fibrin protofibril. Proc Natl Acad Sci USA 78: 4872–4876Google Scholar
  31. Fowler WE, Erickson HP, Hantgan RR, McDonagh J, Hermans J (198lb) Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers. Science 211: 287–289Google Scholar
  32. Francis CW, Markham RE, Jr, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ (1983) Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 102: 220–230PubMedGoogle Scholar
  33. Gold KH, Leinbach RC, Garabedian HD, et al. (1986) Acute coronary reocclusion after thrombolysis with recombinant human tissue type plasminogen activator: prevention by a maintenance infusion. Circulation 73: 347–352PubMedGoogle Scholar
  34. Greenberg CS, Shuman MA (1982) The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem 257: 6096–6101PubMedGoogle Scholar
  35. Greenberg CS, Miraglia CC (1985) The effect of fibrin polymers on thrombin-catalyzed plasma factor XIIIa formation. Blood 66: 466–469PubMedGoogle Scholar
  36. Greenberg CS, Dobson JV, Miraglia CC (1985a) Regulation of plasma factor XIII binding to fibrin in vitro. Blood 66: 1028–1034PubMedGoogle Scholar
  37. Greenberg CS, Miraglia CC, Rickles FR, Shuman MA (1985b) Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. J Clin Invest 75: 1463–1468PubMedGoogle Scholar
  38. Greenberg CS, Achyuthan KE, Fenton JW, II (1987) Factor XIIIa formation promoted by complexing of a-thrombin, fibrin, and plasma factor XIII. Blood 69: 867–871PubMedGoogle Scholar
  39. Hantgan RR,Hermans J (1979) Assembly of fibrin: a light scattering study. J Biol Chem 254: 11272–11281Google Scholar
  40. Harpel PC, Chang TS, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of glu-plasminogen to plasma fibrin I: evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260: 4432–4440PubMedGoogle Scholar
  41. Henschen A, Lottspeich F, Kehl M, Southan C (1983) Covalent structure of fibrinogen. Ann NY Acad Sci 408: 28–43PubMedGoogle Scholar
  42. Hermans J, McDonagh J (1982) Fibrin: structure and interactions. Semin Thromb Hemostasis 8: 11–24Google Scholar
  43. Hewat EA, Tranqui L, Wade RH (1983) Electron microscope structural study of modified fibrin and a related modified fibrinogen aggregate. J Mol Biol 170: 203–222PubMedGoogle Scholar
  44. Hoeprich PD Jr, Doolittle RF (1983) Dimeric half-molecules of human fibrinogen are joined through disulfide bonds in an antiparallel orientation. Biochemistry 22: 2049–2055PubMedGoogle Scholar
  45. Hogg PJ, Jackson CM (1989) Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 86: 3619–3623PubMedGoogle Scholar
  46. Hoylaerts M, Rijken DC, Lijnen HR, Cohen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 257: 2912–2919PubMedGoogle Scholar
  47. Hurlet-Jensen A, Cummins HZ, Nossel HL, Liu CY (1982) Fibrin polymerization and release of fibrinopeptide B by thrombin. Thromb Res 27: 419–427PubMedGoogle Scholar
  48. Husain SS, Hasan AAK, Budzynski AZ (1989) Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Blood 74: 999–1006PubMedGoogle Scholar
  49. Ichinose A, Aoki N (1982) Reversible cross-linking of a2-plasmin inhibitor to fibrinogen by fibrin stabilizing factor. Biochim Biophys Acta 706: 158–164PubMedGoogle Scholar
  50. Janus TJ, Lewis SD, Lorand L, Shafer JA (1983) Promotion of thrombincatalyzed activation of factor XIII by fibrinogen. Biochemistry 26: 6269–6272Google Scholar
  51. Kaminski M, McDonagh J (1983) Studies on the mechanism of thrombin. Interaction with fibrin. J Biol Chem 258: 10530–10535Google Scholar
  52. Kaminski M, McDonagh J (1987) Inhibited thrombins. Interactions with fibrinogen and fibrin. Biochem J 242: 881–887Google Scholar
  53. Kimura S, Aoki N (1986) Cross-linking site in fibrinogen for a2-plasmin inhibitor. J Biol Chem 261: 15591–15595PubMedGoogle Scholar
  54. Korninger C, Cohen D (1981) Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemostas 46: 662–665Google Scholar
  55. Krakow W, Endres GF, Siegel BM, Scheraga HA (1972) An electron microscopic investigation of the polymerization of bovine fibrin monomer. J Mol Biol 71: 95–103PubMedGoogle Scholar
  56. Kudryk B, Reuterby J, Blombäck B (1973) Adsorption of plasmic fragment D to thrombin modified fibrinogen-sepharose. Thromb Res 2: 297–304Google Scholar
  57. Kudryk B, Cohen D, Woods KR, Blombäck B (1974) Evidence for localization of polymerization sites in fibrinogen. J Biol Chem 249: 3322–3325PubMedGoogle Scholar
  58. Laudano AP, Doolittle RF (1978) Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Proc Natl Acad Sci USA 75: 3085–3089PubMedGoogle Scholar
  59. Laudano AP, Doolittle RF (1980) Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization: structural requirements and species differences. Biochemistry 19: 1013–1019PubMedGoogle Scholar
  60. Laurent TC, Blomback B (1958) On the significance of the release of two different peptides from fibrinogen during clotting. Acta Chem Scand 12: 1875–1877Google Scholar
  61. Levin EG (1983) Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 80: 6804–6808PubMedGoogle Scholar
  62. Lewis SD, Janus TJ, Lorand L, Shafer JT (1985) Regulation of the formation of factor XIIIa by its fibrin substrates. Biochemistry 24: 6772–6777PubMedGoogle Scholar
  63. Liu CY, Nossel HL, Kaplan KL (1979a) Defective thrombin binding by abnormal fibrin associated with recurrent thrombosis. Thromb Haemostas 42: 79Google Scholar
  64. Liu CY, Nossel HL, Kaplan KL (1979b) The binding of thrombin by fibrin. J Biol Chem 254:10, 421–10, 425Google Scholar
  65. Liu CY, Koehn JA, Morgan FJ (1985) Characterization of fibrinogen New York I. A dysfunctional fibrinogen with a deletion of Bß 9–72 corresponding exactly to exon 2 of the gene. J Biol Chem 260: 4390–4396PubMedGoogle Scholar
  66. Lorand L, Konishi K (1964) Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys 105: 58–67PubMedGoogle Scholar
  67. Lorand L, Gray AJ, Brown K (1974) Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Comm 56: 914–922PubMedGoogle Scholar
  68. Mary A, Achyuthan KE, Greenberg CS (1987) Factor XIII binds to the A alpha - and B beta - chains in the D-domain of fibrinogen: an immunoblotting study. Biochem Biophys Res. Commun 147: 608–614Google Scholar
  69. Mataciè S, Loewy AG (1968) The identification of isopeptide crosslinks in insoluble fibrin. Biochem Biophys Res Commun 30: 356–362Google Scholar
  70. McDonagh RP, Jr., McDonagh J, Blomback M, Blomback B (1971) Crosslinking of human fibrin: evidence for intermolecular crosslinking involving a-chains. FEBS Lett 14: 33–36PubMedGoogle Scholar
  71. McKee PA, Mattock P, Hill RL (1970) Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci USA 66: 738–744PubMedGoogle Scholar
  72. Mirshahi M, Mirshahi M, Soria J, et al. (1988) Monoclonal antibodies reacting with fibrinogen derivatives inhibit the binding of tissue plasminogen activator to fragment D. In: Mosesson MW, Amrani DL, Siebenlist KR,DiOrio JP, eds. Fibrinogen 3. Biochemistry, biological functions, gene regulation and expression. Amsterdam: Elsevier 147–152Google Scholar
  73. Mirshahi M, Soria J, Soria C, et al. (1989) Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 74: 1025–1030PubMedGoogle Scholar
  74. Moroi M, Aoki N (1976) Isolation and characterization of alpha 2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 251: 5956–5965Google Scholar
  75. Mosesson MW, Hainfeld J. Haschemeyer RH, Wall J (1981) Identification and mass analysis of human fibrinogen molecules and their domains by scanning transmission electron microscopy. J Mol Biol 153: 695–718PubMedGoogle Scholar
  76. Mosesson, MW, Siebenlist KR, DiOrio JP, et al. (1986) Evidence that proximal NH2-terminal portions of fibrinogen Metz (Aa 16 Arg-4Cys) Aa chains are oriented in the same direction. In: Muller-Berghaus G, Scheefers-Borchel U, Selmayr E, Henschen A, eds. Fibrinogen and Its Derivatives Amsterdam: Elsevier 3–15Google Scholar
  77. Mosesson MW, DiOrio JP, Muller MF, et al. (1987) Studies on the ultrastructure of fibrin lacking fibrinopeptide B (13-fibrin). Blood 69: 1073–1081PubMedGoogle Scholar
  78. Mosesson MW, Siebenlist KR, Amrani DL, DiOrio JP (1989a) Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci USA 86: 1 1 13–1117Google Scholar
  79. Mosesson MW, Siebenlist KR, DiOrio JP, Budzynski AZ (1989b) Studies on the conversion of des Bß 1–42 fibrinogen to fibrin and the thrombin binding properties of des Bß 1–42 fibrin. In: Matsuda M, ed. Fibrinogen, Vol. 4. Amsterdam:Elsevier (in press)Google Scholar
  80. Mosesson MW (1990) Fibrin Polymerization and its Regulatory Role in Hemostasis. J Lab Clin Med (in press)Google Scholar
  81. Mullertz S, Clemmensen I (1976) The primary inhibitor of plasmin in human plasma. Biochem J 159: 545–553PubMedGoogle Scholar
  82. Nieuwenhuizen W, Vermond A, Voskiulen M, Traas DW, Verheijen JH (1983a) Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 748: 86–92PubMedGoogle Scholar
  83. Nieuwenhuizen W, Verheijen JH, Vermond A, Chang GTG (1983b) Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. Biochim Biophys Acta 755:531–533Google Scholar
  84. Olexa SA, Budzynski AZ (1980) Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 77: 1374–1378PubMedGoogle Scholar
  85. Olexa SA, Budzynski AZ, Doolittle RF, Cottrell BA, Greene TC (1981) Structure of fragment E species from human cross-linked fibrin. Biochemistry 21: 6139–6145Google Scholar
  86. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER (1988) Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72: 616–620PubMedGoogle Scholar
  87. Pandya BV, Cierniewski CS, Budzynski AZ (1985) Conservation of human fibrinogen conformation after cleavage of the Bß chain NH2-ter minus. J Biol Chem 260: 2994–3000PubMedGoogle Scholar
  88. Pisano JJ, Finlayson JS, Peyton MP (1968) Crosslink in fibrin polymerized by factor XIII: e-(’y-glutamyl)lysine. Science 160: 892–893PubMedGoogle Scholar
  89. Purves LR, Purves M, Brandt W (1987) Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff adder venom (bitis arietans) acting at cross-linked sites of the y-chain. Sequence of carboxy-terminal cyanogen bromide y-chain fragments. Biochemistry 26: 4640–4646Google Scholar
  90. RAnby M (1982) Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 704: 461–469PubMedGoogle Scholar
  91. Saito H (1988) a2-Plasmin inhibitor and its deficiency states. J Lab Clin Med 112:671–678Google Scholar
  92. Sakata Y, Aoki N (1980) Cross-linking of a2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 65: 290–297PubMedGoogle Scholar
  93. Scheraga HA, Laskowski M, Jr (1957) The fibrinogen-fibrin conversion. Adv Prot Chem 12: 1–131Google Scholar
  94. Schwartz ML, Pizzo SV, Hill RL, McKee PA (1973) Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and crosslinking of fibrinogen and fibrin. J Biol Chem 248: 1395–1407Google Scholar
  95. Selmayr E, Thiel W, Muller-Berghaus G (1985) Crosslinking of fibrinogen to immobilized des AA-fibrin. Thromb Res 39: 459–465PubMedGoogle Scholar
  96. Selmayr E, Deffner M, Bachmann L, Muller-Berghaus G (1988) Chromatography and electron microscopy of cross-linked fibrinpolymers-a new model describing the cross-linking at the DD-trans contact of the fibrin molecules. Biopolymers 27: 1733–1748PubMedGoogle Scholar
  97. Shah GA, Ferguson IA, Dhall TZ, Dhall DP (1982) Polydispersion in the diameter of fibres in fibrin networks: consequences on the measurement of mass-length ratio by permeability and turbidity. Biopolymers 21: 1037–1047PubMedGoogle Scholar
  98. Shainoff JR, Dardik BN (1979) Fibrinopeptide B and aggregation of fibrinogen. Science 204: 200–202PubMedGoogle Scholar
  99. Shainoff JR, Dardik BN (1983) Fibrinopeptide B in fibrin assembly and metabolism: physiologic significance in delayed release of the peptide. Ann NY Acad Sci 408: 254–267PubMedGoogle Scholar
  100. Shainoff JR, Valenzuela R, DiBello M, et al. (1988) Combined a-and ‘y-chain crosslinking of fibrinogen and fibrin in vivo and in vitro. Circulation 78 (Suppl II): 513aGoogle Scholar
  101. Shimizu A, Saito Y, Inada Y (1986) Distinctive role of histidine-16 of the Bß chain of fibrinogen in the end-to-end association of fibrin. Proc Natl Acad Sci USA 83: 591–593PubMedGoogle Scholar
  102. Shimizu A, Ferry JD (1988) Ligation of fibrinogen by factor XIIIa with dithiothreitol: mechanical properties of ligated fibrinogen gels. Biopolymers 27: 703–713PubMedGoogle Scholar
  103. Slayter HS (1983) Electron microscopic studies of fibrinogen structure: historical perspectives and recent experiments. Ann NY Acad Sci 408: 131–145PubMedGoogle Scholar
  104. Stryer L, Cohen C, Langridge R (1963) Axial period of fibrinogen and fibrin. Nature (London) 197: 793–794Google Scholar
  105. Suenson E, Lutzen O, Thorsen S (1984) Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140: 513–522PubMedGoogle Scholar
  106. Suenson E, Petersen LC (1986) Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta 870: 510–519PubMedGoogle Scholar
  107. Takagi T, Doolittle RF (1974) Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry 13: 750–756PubMedGoogle Scholar
  108. Tamaki T, Aoki N (1981) Cross-linking of a2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 661: 280–286PubMedGoogle Scholar
  109. Tamaki T, Aoki N (1982) Cross-linking of a2-plasmin inhibitor catalyzed by activated fibrin-stabilizing factor. J Biol Chem 257:14767–14772PubMedGoogle Scholar
  110. Timmis GC, Mammen EF, Ramos RG, et al. (1986) Hemmorhage vs rethrombosis after thrombolysis for acute myocardial infarction. Arc Int Med 146: 667–672Google Scholar
  111. Todd AS (1959) The histological localisation of fibrinolysin activator. J Pathol Bacteriol 78: 281–283PubMedGoogle Scholar
  112. Tran-Thang C, Kruitkof EKO, Bachmann F (1984) Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. J Clin Invest 74: 2009–2016PubMedGoogle Scholar
  113. Tran-Thang C, Kruitkof EKO, Atkinson J, Bachmann F (1986) High affinity binding sites for glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem 160: 599–604PubMedGoogle Scholar
  114. Vali Z, Scheraga HA (1988) Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry 27: 1956–1963PubMedGoogle Scholar
  115. Verheijen JH, Nieuwenhuizen W, Wijngaards G (1982) Activation of plasminogen by tissue activator is increased specifically in the presence of certain soluble fibrin(ogen) fragments. Thromb Res 27: 377–385PubMedGoogle Scholar
  116. Voskiulen M, Vermond A, Veeneman GH, et al. (1987) Fibrinogen lysine residue Aa 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 262: 5944–5946Google Scholar
  117. Weitz JI, Cruickshank MK, Thong B, et al. (1988) Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 82: 1700–1707PubMedGoogle Scholar
  118. Williams RC (1981) Morphology of bovine fibrinogen monomers and fibrin oligomers. J Mol Biol 150: 399–408PubMedGoogle Scholar
  119. Williams RC (1983) Morphology of fibrinogen monomers and of fibrin polymers. Ann NY Acad Sci 408: 180–193PubMedGoogle Scholar
  120. Williams DO, Weitz JI, Cruickshank MK, et al. (1986) Intravenous recombinant tissue type plasminogen activator in patients with acute myocardial infarction. A report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 73: 338–346PubMedGoogle Scholar
  121. Wilner GD, Danitz MP, Mudd MS, Hsieh K-H, Fenton JW, II (1981) Selective immobilization of a-thrombin by surface-bound fibrin. J Lab Clin Med 97: 403–411PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Michael W. Mosesson
    • 1
  1. 1.Sinai Samaritan Medical CenterUniversity of Wisconsin Medical School-Milwaukee Clinical CampusMilwaukeeUSA

Personalised recommendations